Investigational drug · Phase 3
JADE101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy (IgAN), IgA Nephropathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "JADE101"
First trial start
2026
May 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JADE101", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy (IgAN)
- IgA Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "JADE101" as an intervention, largest first.
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyPivotal-lookingRecruiting
Jade Biosciences, Inc.Industry
NCT07902817 · 480 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: JADE101; Placebo · For: IgA Nephropathy (IgAN)
Sites: Arvada, Colorado; Lauderdale Lakes, Florida; Atlanta, Georgia · 4 sites in all
Jade Biosciences, Inc.Industry
NCT07525947 · 40 participants (planned) · Start May 1, 2026 · Primary completion May 2027
Drug: JADE101 · For: Healthy Volunteers (HV)
Sites: Glendale, California
Jade Biosciences, Inc.Industry
NCT07059312 · 32 participants · Start Aug 17, 2025 · Primary completion Oct 21, 2026
Drug: JADE101; Placebo · For: Healthy Volunteers
Sites: Auckland, New Zealand
Jade Biosciences, Inc.Industry
NCT07541287 · 30 participants (planned) · Start May 19, 2026 · Primary completion Jan 2029
Drug: JADE101 · For: IgA Nephropathy
Sites: Chula Vista, California; Arvada, Colorado; Denver, Colorado · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgA Nephropathy (IgAN)
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- SC0062Phase 31 trial
Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
- SLN12140Phase 22 trials
Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.